Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota

Jun 24, 2015Nature communications

Ganoderma lucidum lowers obesity in mice by changing gut bacteria

AI simplified

Abstract

A water extract of Ganoderma lucidum mycelium reduces body weight, inflammation, and insulin resistance in mice fed a high-fat diet.

  • Ganoderma lucidum extract reverses , indicated by decreased Firmicutes-to-Bacteroidetes ratios and lower levels of endotoxin-bearing Proteobacteria.
  • The extract maintains intestinal barrier integrity and reduces metabolic endotoxemia.
  • The anti-obesity and microbiota-modulating effects can be transmitted from treated mice to those fed a high-fat diet through fecal transfer.
  • High molecular weight polysaccharides (>300 kDa) from the extract exhibit similar effects on obesity and gut microbiota.
  • These findings suggest potential use of Ganoderma lucidum and its polysaccharides as prebiotic agents to address obesity-related metabolic disorders.

AI simplified

Key numbers

8% WEGL
Weight Reduction
Mice treated with 8% WEGL showed reduced body weight and fat accumulation.
TNF-α
Cytokine Decrease
WEGL treatment decreased pro-inflammatory cytokine levels in liver and adipose tissues.

Full Text

What this is

  • Ganoderma lucidum (WEGL) reduces obesity in mice by altering gut microbiota composition.
  • Mice fed a high-fat diet (HFD) showed decreased body weight and fat accumulation with WEGL supplementation.
  • WEGL also improved inflammatory markers and insulin resistance, suggesting potential therapeutic benefits for obesity-related disorders.

Essence

  • WEGL supplementation in HFD-fed mice significantly reduces body weight and fat accumulation while modulating gut microbiota and inflammation. High molecular weight polysaccharides from WEGL are identified as key active components.

Key takeaways

  • WEGL decreases body weight and fat accumulation in HFD-fed mice. Mice receiving 8% WEGL showed a dose-dependent reduction in weight gain and fat accumulation compared to HFD controls.
  • WEGL modulates inflammatory cytokine levels. Treatment reduced pro-inflammatory cytokines such as TNF-α and IL-6 in liver and adipose tissues of HFD-fed mice.
  • High molecular weight polysaccharides (>300 kDa) from WEGL are effective in reducing obesity. These polysaccharides produced similar anti-obesity effects as the whole WEGL extract.

Caveats

  • The study is limited to a mouse model, which may not fully replicate human obesity mechanisms. Further research is needed to confirm these effects in human subjects.

Definitions

  • Gut dysbiosis: An imbalance in the gut microbiota composition, often associated with obesity and metabolic disorders.

AI simplified

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free